Skip to Content

Orencia Approval History

  • FDA approved: Yes (First approved December 23rd, 2005)
  • Brand name: Orencia
  • Generic name: abatacept
  • Dosage form: Injection
  • Company: Bristol-Myers Squibb Company
  • Treatment for: Rheumatoid Arthritis

Orencia (abatacept) is a selective costimulation modulator indicated for the treatment of rheumatoid arthritis (RA).

Development History and FDA Approval Process for Orencia

Jul 31, 2011Approval U.S. Food and Drug Administration Approves Subcutaneous Formulation of Orencia (abatacept), a Proven Non-Anti-TNF Biologic for Adults with Moderate to Severe Rheumatoid Arthritis
Dec 23, 2005Approval Orencia Bristol-Myers Squibb Company - Treatment for Rheumatoid Arthritis
Sep  6, 2005Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on Orencia (Abatacept), an Investigational Selective Modulator of T-Cell Co-Stimulation for Rheumatoid Arthritis
Dec 23, 2004Bristol-Myers Squibb Provides Regulatory Update for Abatacept

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.